Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2017, Article ID 4623964, 3 pages
Case Report

Systemic Treatment of Metastatic Conjunctival Melanoma

1Department of Medical Oncology, Hospital Professor Doutor Fernando Fonseca E.P.E., 2720-276 Amadora, Portugal
2Department of Medical Oncology, Instituto Português de Oncologia de Lisboa, Francisco Gentil E.P.E., 1099-023 Lisboa, Portugal
3Department of Ophthalmology, Centro Hospitalar Lisboa Central E.P.E., 1150-199 Lisboa, Portugal

Correspondence should be addressed to Simão Pinto Torres; moc.liamg@serrotpoamis

Received 12 June 2017; Accepted 18 September 2017; Published 26 October 2017

Academic Editor: Constantine Gennatas

Copyright © 2017 Simão Pinto Torres et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Conjunctival melanoma (CM) is an exceptionally rare tumor, with a propensity for local and distant recurrence, with the lungs, skin, liver, and brain being the most common sites of metastasis. Recent progress in systemic treatments, with checkpoint inhibitors and targeted therapies blocking BRAF and MEK, has redefined the standard of care of advanced unresectable and metastatic melanoma. Although most trials did not include patients with conjunctival melanoma, its close molecular and genetic relationship to cutaneous melanoma might suggest a similar response to these novel agents. The authors describe two uncommon cases of metastatic conjunctival melanomas with distinct genetic profiles and, as such, submitted to different systemic treatments.